189 related articles for article (PubMed ID: 35438039)
1. Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review.
Bencina G; Fues Wahl H; Tsoumani E; Salomonsson S
Hum Vaccin Immunother; 2022 Nov; 18(5):2060017. PubMed ID: 35438039
[TBL] [Abstract][Full Text] [Related]
2. Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature.
Arya S; Norton N; Kaushik P; Brandtmüller A; Tsoumani E
Hum Vaccin Immunother; 2023 Dec; 19(3):2279394. PubMed ID: 38014651
[TBL] [Abstract][Full Text] [Related]
3. Evolution of Pneumococcal Vaccine Recommendations and Criteria for Decision Making in 5 Western European Countries and the United States.
Noharet-Koenig R; Lasota K; Faivre P; Langevin E
MDM Policy Pract; 2023; 8(1):23814683231174432. PubMed ID: 37274614
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
5. Indirect (herd) protection, following pneumococcal conjugated vaccines introduction: A systematic review of the literature.
Tsaban G; Ben-Shimol S
Vaccine; 2017 May; 35(22):2882-2891. PubMed ID: 28449971
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
7. Strengthening national decision-making on immunization by building capacity for economic evaluation: Implementing ProVac in Europe.
Blau J; Hoestlandt C; D Clark A; Baxter L; Felix Garcia AG; Mounaud B; Mosina L
Vaccine; 2015 May; 33 Suppl 1():A34-9. PubMed ID: 25919171
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of pediatric pneumococcal conjugate vaccines: a comparative assessment of decision-making tools.
Chaiyakunapruk N; Somkrua R; Hutubessy R; Henao AM; Hombach J; Melegaro A; Edmunds JW; Beutels P
BMC Med; 2011 May; 9():53. PubMed ID: 21569402
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
[TBL] [Abstract][Full Text] [Related]
12. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution.
Izurieta P; Bahety P; Adegbola R; Clarke C; Hoet B
Expert Rev Vaccines; 2018 Jun; 17(6):479-493. PubMed ID: 29241390
[TBL] [Abstract][Full Text] [Related]
13. Modeling Possible Inclusion of Pneumococcal Conjugate Vaccine into the National Immunization Program for Infants in India.
Ghia C; Wasserman M; Fletcher M; Farkouh R; Rambhad G
Value Health Reg Issues; 2018 May; 15():99-105. PubMed ID: 29655052
[TBL] [Abstract][Full Text] [Related]
14. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
15. Budget impact analysis of pneumococcal conjugate vaccines in Colombia.
Gomez J; Moreno LE; Constenla D; Caceres D; Rodriguez E
Expert Rev Pharmacoecon Outcomes Res; 2021 Apr; 21(2):255-263. PubMed ID: 33249948
[No Abstract] [Full Text] [Related]
16. Impact and cost effectiveness of pneumococcal conjugate vaccine in India.
Krishnamoorthy Y; Eliyas SK; Nair NP; Sakthivel M; Sarveswaran G; Chinnakali P
Vaccine; 2019 Jan; 37(4):623-630. PubMed ID: 30587430
[TBL] [Abstract][Full Text] [Related]
17. A reflection on invasive pneumococcal disease and pneumococcal conjugate vaccination coverage in children in Southern Europe (2009-2016).
Moreira M; Castro O; Palmieri M; Efklidou S; Castagna S; Hoet B
Hum Vaccin Immunother; 2017 Jun; 13(6):1-12. PubMed ID: 27996380
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness and cost utility analysis of three pneumococcal conjugate vaccines in children of Peru.
Gomez JA; Tirado JC; Navarro Rojas AA; Castrejon Alba MM; Topachevskyi O
BMC Public Health; 2013 Oct; 13():1025. PubMed ID: 24171921
[TBL] [Abstract][Full Text] [Related]
20. The worldwide impact of the seven-valent pneumococcal conjugate vaccine.
Fitzwater SP; Chandran A; Santosham M; Johnson HL
Pediatr Infect Dis J; 2012 May; 31(5):501-8. PubMed ID: 22327872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]